Nephrology Doctors in Columbus, IN Accepting Medicare

4 Nephrology doctors found. Showing 1 - 4

Raymond Lee Kiser, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2400 17th St, Columbus, IN 47201 Phone: 812-379-4441    Fax: 812-375-3203

Russell James Pikus, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 940 N Marr Rd Ste B, Columbus, IN 47201 Phone: 812-375-0272    Fax: 812-375-1093

Deepak Jasuja, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2400 17th St, Columbus, IN 47201 Phone: 812-375-0272    Fax: 812-375-1093

Kiran Kumar Chintam, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 940 N Marr Rd Ste B, Columbus, IN 47201 Phone: 812-375-0272

News Archive

Brain microhemorrhages more common among high altitude cerebral edema survivors

New magnetic resonance imaging (MRI) research shows that mountain climbers who experience a certain type of high altitude sickness have traces of bleeding in the brain years after the initial incident, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

MMP9 enzyme could suppress tumors in colitis associated cancer, new study finds

An enzyme that plays an active role in inflammation could be a natural way to suppress tumors and ulcers in the colon that are found in colitis associated cancer (CAC), a type of colorectal cancer that is driven by chronic inflammation, according to a new study.

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

Read more Medical News

› Verified 6 days ago